QCG
RCUS icon

Quadrant Capital Group’s Arcus Biosciences RCUS Stock Holding History

Quadrant Capital Group’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.5K Buy
1,088
+9
+0.8% +$194 ﹤0.01% 1951
2025
Q4 		$25.7K Hold
1,079
– – ﹤0.01% 1910
2025
Q3 		$14.7K Buy
+1,079
New +$11.2K ﹤0.01% 2048
2025
Q2 		– Sell
-3,721
Closed -$29.2K – 2306
2025
Q1 		$29.2K Buy
3,721
+3,643
+4,671% +$42.2K ﹤0.01% 1911
2024
Q4 		$1.16K Sell
78
-57
-42% -$931 ﹤0.01% 2575
2024
Q3 		$2.06K Sell
135
-13
-9% -$205 ﹤0.01% 2494
2024
Q2 		$2.25K Sell
148
-5
-3% -$81 ﹤0.01% 2455
2024
Q1 		$2.89K Sell
153
-288
-65% -$4.98K ﹤0.01% 2434
2023
Q4 		$8.42K Sell
441
-181
-29% -$2.89K ﹤0.01% 2129
2023
Q3 		$11.2K Buy
622
+53
+9% +$1.06K ﹤0.01% 1943
2023
Q2 		$11.6K Buy
569
+300
+112% +$5.71K ﹤0.01% 1940
2023
Q1 		$4.91K Sell
269
-86
-24% -$1.64K ﹤0.01% 2243
2022
Q4 		$7.34K Buy
355
+114
+47% +$3.14K ﹤0.01% 2092
2022
Q3 		$6K Buy
241
+223
+1,239% +$5.9K ﹤0.01% 2089
2022
Q2 		$0 Buy
+18
New +$441 ﹤0.01% 2691

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Quadrant Capital Group's RCUS Position: Q1 2026 in Review

Quadrant Capital Group increased its Arcus Biosciences (RCUS) stake by 0.83% in Q1 2026, buying an estimated $194 and bringing the position to 1,088 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1951.

Quadrant Capital Group first reported a position in RCUS in Q2 2022 and has held it in 15 quarters since. The position peaked at $29.2K in Q1 2025. 210 funds tracked by Wall St. Rank hold RCUS as of Q1 2026.

  • Quadrant Capital Group held 1,088 shares of Arcus Biosciences worth $23.5K as of Q1 2026.
  • Quadrant Capital Group bought 9 Arcus Biosciences shares in Q1 2026, an estimated $194.
  • Arcus Biosciences made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #1951 holding.
  • Quadrant Capital Group first reported a position in Arcus Biosciences in Q2 2022 and has held it in 15 quarters since.
  • Quadrant Capital Group's Arcus Biosciences position peaked at $29.2K in Q1 2025.
  • 210 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.